Stryker Corporation $SYK Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 32.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 215,547 shares of the medical technology company’s stock after selling 102,917 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.06% of Stryker worth $59,359,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of SYK. State Street Corp increased its stake in shares of Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after acquiring an additional 183,400 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Stryker by 0.6% in the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares during the period. Bank of America Corp DE bought a new position in Stryker during the 2nd quarter worth approximately $1,404,284,000. Royal Bank of Canada boosted its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Stryker by 21.8% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after acquiring an additional 481,175 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of SYK stock opened at $307.41 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33. The company’s 50 day moving average price is $295.86 and its two-hundred day moving average price is $311.96. The company has a market capitalization of $117.91 billion, a P/E ratio of 31.86, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SYK. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. TD Cowen cut their target price on shares of Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a report on Tuesday, September 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Finally, Citizens Jmp decreased their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Insider Activity at Stryker

In other Stryker news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.